Aloe-emodin inhibits adipocyte differentiation and maturation during in vitro human mesenchymal stem cell adipogenesis.
Subash-Babu P., Alshatwi AA.
Laboratory Study, published in J Biochem Mol Toxicol (2012) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- J Biochem Mol Toxicol (2012)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 22645054
- DOI
- 10.1002/jbt.21415
Abstract (original English)
In this study, we examined the effects of Aloe-emodin (AE) on the inhibition of adipocyte differentiation during 3-isobutyl-1-methylxanthine (IBMX)-induced adipocyte differentiation in human mesenchymal stem cells (hMSCs). AE treatment (5, 10, and 20 µM) of preadipocyte cells resulted in a significant (p < 0.05) decrease in glycerol phosphate dehydrogenase and triglyceride levels as well as an increase in lactate dehydrogenase activity and attenuated lipid accumulation compared with untreated differentiated adipocytes. Using quantitative reverse transcription polymerase chain reaction, we studied the mRNA expression levels of resistin, adiponectin, aP(2), lipoprotein lipase, PPARγ, and tumor necrosis factor-α in hMSCs undergoing adipocyte differentiation; treatment with AE decreased the expression of these adipogenic genes and decreased adipocyte differentiation. In addition, AE suppresses the differentiation of hMSCs into adipocytes by downregulating PPARγ and C/EBPα expressions. AE significantly inhibited hMSCs proliferation and preadipocyte differentiation within the first 2 days of treatment, indicating that the antiadipogenic effect.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.